Are sodium-glucose co-transporter 2 (SGLT-2) inhibitors a class I therapy for heart failure with preserved ejection fraction?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

SGLT-2 Inhibitors Are Class 2a (Not Class I) for Heart Failure with Preserved Ejection Fraction

SGLT-2 inhibitors receive a Class 2a recommendation (not Class I) for HFpEF in current North American guidelines, though they represent the strongest evidence-based therapy available for this condition. The distinction matters: Class 2a means "reasonable to use" with moderate-quality evidence, while Class I would indicate "should be used" with high-quality evidence 1, 2.

Current Guideline Classification

The 2024 ACC/AHA performance measures explicitly state that SGLT-2 inhibitors have a Class 2a recommendation for HFpEF (LVEF >40%), indicating they "can be beneficial in decreasing HF hospitalizations and cardiovascular mortality" 1. This is consistent across major North American guidelines 2.

In contrast, SGLT-2 inhibitors ARE Class I for HFrEF (LVEF ≤40%), where they represent foundational guideline-directed medical therapy alongside ARNI/ACEi/ARB, beta-blockers, and MRAs 3.

Why Not Class I for HFpEF?

The evidence base differs between HFrEF and HFpEF:

  • Mortality benefit: SGLT-2 inhibitors significantly reduce cardiovascular and all-cause mortality in HFrEF 4, 3. In HFpEF, the primary benefit is hospitalization reduction (21-29% decrease), with less robust mortality signals 4, 5.

  • Effect size: The hazard ratio for the primary composite endpoint in HFpEF trials (EMPEROR-Preserved: HR 0.79; DELIVER: HR 0.82) shows benefit but is less dramatic than in HFrEF 6, 4.

  • Quality of evidence: While the trials are well-conducted, the outcomes prioritized for Class I recommendations (mortality and quality of life) show more modest effects in HFpEF compared to HFrEF 4.

The Most Recent Evidence (2025)

The 2025 Canadian CCS/CHFS guideline provides the most current framework 6. They classify SGLT-2 inhibitors as first-tier therapy for HFnrEF (non-reduced EF, which includes HFpEF), placing them alongside ARNIs, ARBs, and MRAs in their treatment algorithm. Specific agents recommended:

  • Dapagliflozin 10 mg daily (based on DELIVER trial)
  • Empagliflozin 10-25 mg daily (based on EMPEROR-Preserved trial)

The DELIVER trial showed dapagliflozin reduced the primary outcome (HF hospitalization/urgent HF visit/CV death) by 18% (HR 0.82,95% CI 0.73-0.92), driven primarily by worsening HF events (HR 0.79) 6.

Practical Implementation Algorithm

Start SGLT-2 inhibitors in ALL symptomatic HFpEF patients unless contraindicated:

Absolute Contraindications:

  • Type 1 diabetes 3
  • eGFR <20 mL/min/1.73 m² 3, 4, 3
  • Active dialysis 4

Initiation Strategy:

  1. Start early - no need to wait for optimization of other therapies 6
  2. Dapagliflozin 10 mg daily OR Empagliflozin 10 mg daily (can increase to 25 mg) 6
  3. Monitor within 1-3 months: eGFR may drop up to 15% transiently, typically resolves 3

Common Pitfalls to Avoid:

  • Don't delay initiation waiting for "optimal" background therapy - the 2025 guidelines emphasize no specific sequence is required 6
  • Don't stop for mild eGFR decline - temporary reductions up to 15% are expected and resolve 3
  • Don't withhold in non-diabetics - benefits are independent of diabetes status 6, 4
  • Hold during "sick days" - dehydrating illness, acute kidney injury, or major surgery 3

Monitoring:

  • Genital mycotic infections (10-15% in women, higher in uncircumcised men) - treat with antifungals, rarely requires discontinuation 3
  • Euglycemic DKA (0.1% incidence) - suspect if unexplained metabolic acidosis even with normal glucose 3
  • Volume status - particularly when combined with diuretics 3

Evidence Across the LVEF Spectrum

A critical nuance: empagliflozin's benefit was attenuated when LVEF >65%, while dapagliflozin showed consistent benefit across the entire LVEF spectrum 5. However, pooled meta-analyses demonstrate significant reduction in HF hospitalizations and cardiovascular death across all LVEF ranges 4, 5.

Bottom Line for Clinical Practice

Prescribe SGLT-2 inhibitors for all symptomatic HFpEF patients (LVEF >40%) unless contraindicated. While technically Class 2a rather than Class I, they represent the only disease-modifying therapy with proven benefit for reducing HF hospitalizations in this population 6, 4. The distinction between Class 2a and Class I reflects the evidence base (primarily hospitalization reduction vs. mortality benefit), not a lack of clinical importance. In real-world practice, SGLT-2 inhibitors should be considered foundational therapy for HFpEF, just as they are for HFrEF.

References

Related Questions

How should I manage a patient with heart failure with preserved ejection fraction on a sodium‑glucose co‑transporter‑2 (SGLT‑2) inhibitor and spironolactone who has a serum creatinine increase of less than 30% after one week?
Can an SGLT‑2 inhibitor be initiated in a patient with heart failure with reduced ejection fraction and chronic liver disease who has an estimated glomerular filtration rate of 25 mL/min and a serum bicarbonate of 15 mEq/L?
What are the benefits of sodium‑glucose cotransporter‑2 (SGLT2) inhibitors in patients with heart failure with reduced ejection fraction?
In an elderly (>80 year‑old) patient with heart failure with preserved ejection fraction, severe mitral regurgitation, moderate tricuspid regurgitation, aortic regurgitation, and hypernatremia who refuses oral fluids, can fluid accumulate despite no oral intake?
Can dapagliflozin and empagliflozin be prescribed for patients with heart failure with reduced ejection fraction who do not have diabetes mellitus?
How should a patient with bleeding varicose veins after trauma that is now controlled be managed in the emergency department?
What is the appropriate treatment for a 27‑year‑old patient with chronic kidney disease on hemodialysis who has markedly elevated intact parathyroid hormone and presents with diffuse joint and muscle pain?
What are the causes and health risks of lead poisoning, its significance in Iowa, and the CDC recommendations for screening and treatment?
How should I document the root‑cause analysis (RCA) and corrective‑preventive actions (CAPA) for a transfusion‑related allergic reaction, and is routine pre‑medication with chlorpheniramine (AVIL) and hydrocortisone appropriate for every patient receiving multiple units of packed red blood cells and fresh frozen plasma?
What are the known precursors of appendiceal mucinous carcinoma?
What renal dose modifications are recommended for trimethoprim‑sulfamethoxazole (cotrimoxazole)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.